This is early beta for now! Can't handle all templates properly
Hankkija
Vastaanotettu Hilmaan | 2019-12-31 |
Ilmoituksen numero | 2019-013008 |
TED numero | 2019/S 112-274817 |
Ostajaorganisaatio | National Institute for Health and Welfare (2229500-6 ) PL 30 FI-00271 Helsinki https://thl.fi/en/web/thlfi-en |
Hankinnan otsikkotiedot | Contract for the procurement of Human Papillomavirus Vaccine (HPV) 2019-2020 (2020-2021) |
Hankinnan yhteenlaskettu kokonaisarvo koko ajalle (ilman alv:ta) arvio | |
Hankinnan yhteenlaskettu kokonaisarvo koko ajalle (ilman alv:ta) lopullinen | 1 447 600 EUR |
Alkuperäinen ilmoitus | https://www.hankintailmoitukset.fi/en/public/procurement/11303/notice/24383/overview |
Originaali JSON tietue | 24383.json |
Ostettava
Hankinnan lyhyt kuvaus | The purpose of STM and the Customer is to procure Human Papillomavirus Vaccine (HPV) required for the National Vaccination Programme in Finland. The Customer will implement the procurement on STM´s side. The roles of STM and Customer are described in more detail in section "Presentation of the contracting authority". The subject of procurement and the mandatory requirements relating to it are described in detail in this Invitation to Tender and its annexes. The contract will be awarded to one Supplier based on a comparison of tenders. CONTRACT PERIOD The contract period is one year (during 2019-2020). The Contract period shall enter into force once the contract has been signed, and expire when all contractual duties have been performed. Please notice that in the section "II.2.5. Award criteria" Price means the reference price. Tenders will be compared in the manner described in section "Grounds for decision" of the Invitation to tender. |
Hankintanimikkeistö (CPV) pää | |
Hankintanimikkeistö (CPV) muut | |
Aluekoodi | FI |
Pääasiallinen suorituspaikka |
Sopimukset
Päätös päivämäärä | 2019-03-25 |
Sopimusnumero | |
Myyjät | GlaxoSmithKline Oy (FI), 0108378-4 |